Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development
Sanofi Has Collaborated With Radiomedix And Orano Med For Alphamedix (212Pb-DOTAMTATE), For Neuroendocrine Tumors, Radiomedix And Orano Med Will Receive An Upfront Payment Of €100M And Up To €220M In Sales Milestones
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.